<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514954</url>
  </required_header>
  <id_info>
    <org_study_id>BC3-CT019</org_study_id>
    <nct_id>NCT02514954</nct_id>
  </id_info>
  <brief_title>Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus</brief_title>
  <official_title>Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adocia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adocia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Each subject will be randomly allocated to a sequence of two treatments applied at two
      separate dosing visits. At each dosing visit subjects will be injected with individualised
      doses of either BioChaperone® Combo or Humalog® Mix 25 immediately before ingesting a
      standardised mixed meal [(t=0 min) start of the meal]. Insulin doses will be identical at
      both dosing visits of one individual and will be administered subcutaneously in the abdominal
      region. Subjects will be asked to consume a standardised meal (e.g. pizza) for dinner at home
      in the evening before each dosing visit. Subjects will attend the clinical site in a fasted
      state in the morning of each dosing day and stay at the clinical trial centre until 10-hour
      after dosing (standardised test-meal procedure has been terminated after 6h). The two dosing
      visits will be separated by a wash-out period of 5-15 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delta AUCBG,0-2h</measure>
    <time_frame>2 hours</time_frame>
    <description>Incremental area under the blood glucose concentration-time curve from 0-2 hours after a standardised meal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delta AUCBG,0-6h</measure>
    <time_frame>6 hours</time_frame>
    <description>Incremental area under the blood glucose concentration-time curve from 0-6 hours after a standardised meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BGmax</measure>
    <time_frame>6 hours</time_frame>
    <description>Maximum blood glucose concentration after a standardised meal (0-6 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tBGmax</measure>
    <time_frame>6 hours</time_frame>
    <description>Time to maximum blood glucose concentration after a standardised meal (0-6 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCLisp,0-6h,</measure>
    <time_frame>6 hours</time_frame>
    <description>Area under the plasma insulin lispro concentration-time curve from 0-6 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCGlarg,0-6h</measure>
    <time_frame>6 hours</time_frame>
    <description>Area under the plasma insulin glargine concentration-time curve from 0-6 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,Lisp</measure>
    <time_frame>6 hours</time_frame>
    <description>Maximum observed plasma insulin lispro concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,Glarg</measure>
    <time_frame>6 hours</time_frame>
    <description>Maximum observed plasma insulin glargine concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local tolerability</measure>
    <time_frame>Up to 7 weeks</time_frame>
    <description>Number and intensity of injection site reactions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>BioChaperone® Combo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 single dose 400 U/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog® Mix25</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 single dose 100 U/mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biochaperone® Combo</intervention_name>
    <description>Subcutaneous injection of an individualized dose</description>
    <arm_group_label>BioChaperone® Combo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humalog® Mix25</intervention_name>
    <description>Subcutaneous injection of an individualized dose</description>
    <arm_group_label>Humalog® Mix25</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus (as diagnosed clinically) &gt;= 12 months.

          -  Treated with multiple daily insulin injections or CSII &gt;= 12 months.

          -  Current total daily insulin treatment &lt; 1.2 (I)U/kg/day.

          -  Current total daily bolus insulin treatment &lt; 0.7 (I)U/kg/day.

          -  Usual Insulin bolus dose between 0.8 and 2 (I)U per 10 g CH (both inclusive).
             Expecting prandial insulin dose range for standardised meal test between 5 and 12
             (I)U.

          -  BMI 18.5-28.0 kg/m^2 (both inclusive).

          -  HbA1c &lt;= 9.0% by local laboratory analysis

          -  Fasting C-peptide &lt;= 0.3 nmol/L.

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to trial products or related products.

          -  Type 2 diabetes mellitus.

          -  Previous participation in this trial. Participation is defined as randomised.

          -  Participation in any Clinical Trial within 3 months prior to this trial.

          -  Clinically significant abnormal haematology, biochemistry, lipids, or urinalysis
             screening tests, as judged by the Investigator considering the underlying disease.

          -  Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea,
             vomiting, heartburn or diarrhoea), as judged by the Investigator.

          -  Known slowing of gastric emptying and or gastrointestinal surgery that in the opinion
             of the investigator might change gastrointestinal motility and food absorption.

          -  Unusual meal habits and special diet requirements or unwillingness to eat the food
             provided in the trial.

          -  Women of child bearing potential, not willing to use contraceptive methods.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrike Hövelmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut Für Stoffwechselfforschung GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2015</study_first_submitted>
  <study_first_submitted_qc>July 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2015</study_first_posted>
  <last_update_submitted>November 5, 2015</last_update_submitted>
  <last_update_submitted_qc>November 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

